A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

NCT05608291 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1564

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Fianlimab
DRUG: Cemiplimab
DRUG: Pembrolizumab
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals